New App can Help Doctors Predict Risk of Preterm Birth

A new app called QUiPP could help doctors to better identify women at risk of giving birth prematurely. The app, developed at King's College London, was tested in two studies of high-risk women being monitored at ante-natal clinics. Worldwide 15 million babies are born preterm (before 37 weeks) each year and over a million of these die of prematurity-related complications. A number of factors are used to determine if a woman is at risk of giving birth prematurely, including a history of preterm births or late miscarriages. Two further factors which doctors can consider are the length of cervix and levels of a biomarker found in vaginal fluid known as fetal fibronectin, which are typically tested from 23 weeks. The investigators have further developed the fetal fibronectin test to be accurately used from the first half of pregnancy.

The app developed at King's uses an algorithm which combines the gestation of previous pregnancies and the length of the cervix with levels of fetal fibronectin to classify a woman's risk. The first study focused on women deemed to be a high risk of preterm birth, usually because of a previous early pregnancy, despite not showing any symptoms. The second study predicted the likelihood of early delivery in a group of women showing symptoms of early labour which often doesn't progress to real labour.

In the first study, published in the journal Ultrasound in Obstetrics & Gynecology, researchers collected data from 1,249 women at high risk for pre-term birth attending pre-term surveillance clinics. The model was developed on the first 624 consecutive women and validated on the subsequent 625. The estimated probability of delivery before 30, 34 or 37 weeks' gestation and within two or four weeks of testing for fetal fibronectin was calculated for each patient and analyzed as a predictive test for the actual occurrence of each event.

In the second study, also published in the journal Ultrasound in Obstetrics & Gynecology, data from 382 high-risk women was collected. The model was developed on the first 190 women and validated on the remaining 192. Probabilities of delivering early were estimated as above.

In both studies, the app was found to perform well as a predictive tool, and far better than each component (previous pregnancy, cervical length or fetal fibronectin) taken alone.

The authors conclude that the app can be used by clinicians to improve the estimation of the probability of premature delivery (before 34 weeks' gestation or within two weeks of the fetal fibronectin test) and to potentially tailor clinical management decisions.

However, further work is needed to clinically evaluate the model in practice, and to ascertain whether interventions improve the pregnancy outcome for women identified as high risk by the app.

Professor Andrew Shennan, lead author who is Professor of Obstetrics at King's College London and consultant obstetrician at Guy's and St Thomas' NHS Foundation Trust, said:

"Despite advances in prenatal care the rate of preterm birth has never been higher in recent years, including in the US and UK, so doctors need reliable ways of predicting whether a woman is at risk of giving birth early. It can be difficult to accurately assess a woman's risk, given that many women who show symptoms of preterm labour do not go on to deliver early.

"The more accurately we can predict her risk, the better we can manage a woman's pregnancy to ensure the safest possible birth for her and her baby, only intervening when necessary to admit these 'higher risk' women to hospital, prescribe steroids or offer other treatments to try to prevent an early birth."

QUiPP is available to download for free from the Apple store.

Most Popular Now

Zebra Announces Regulatory Approval of i…

Zebra Medical Vision, the leading machine learning imaging analytics company, announces that the company has been granted the CE approval and subsequent release of its Deep Learning Analytics Engine in...

Mind-Controlled Device Helps Stroke Pati…

Stroke patients who learned to use their minds to open and close a device fitted over their paralyzed hands gained some control over their hands, according to a new study...

Philips and Illumina Team Up with Navica…

Royal Philips (NYSE: PHG, AEX: PHIA) and Navican, an Intermountain Healthcare company, today signed an agreement to deploy a precision health informatics solution that will allow hospitals and health systems...

Artificial Intelligence to Assist in the…

The University of Tampere and TAYS (Tampere University Hospital) Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart...

Boehringer Ingelheim Builds Digital Lab …

With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together...

NHS Organisations to Access IMS MAXIMS C…

Award-winning electronic patient record (EPR) provider IMS MAXIMS has announced the availability of its cloud services on the latest iteration of the UK Government's G Cloud Framework. NHS organisations looking...

Anyone can Become More Curious. Is that …

Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious". Driven by the company’s curiosity initiative, which measured and described...

EC Open Call FETOPEN-01-2016-2017: FET-O…

The successful exploration of new foundations for radically new future technologies requires supporting a large set of early stage, high risk visionary science and technology projects to investigate new ideas...

Home Monitoring of Blood Sugar Did Not I…

Self-monitoring of blood glucose levels in patients with type 2 diabetes who are not treated with insulin did not improve glycemic control or health-related quality of life after one year...

Call for Applications: 2017 Lyfebulb-Nov…

For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives...

New Cellular Imaging Paves Way for Cance…

Researchers at the Universities of York and Leiden have pioneered a technique which uses florescent imaging to track the actions of key enzymes in cancer, genetic disorders and kidney disease...

Bayer Grants4Apps® Dealmaker Berlin 2017

Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts...